Fatty acids and neuropsychiatric disorders
© Puri; licensee BioMed Central Ltd. 2008
Published: 17 April 2008
In 1937, after qualifying as a medical doctor and before taking up his appointment as a fellow at Magdalen College, Oxford, Hugh Sinclair visited Herbert Evans, the co-discoverer with Katherine Scott Bishop of vitamin E, and became interested in the possibility that some fatty acid deficiencies might account for the rise in ischaemic heart disease in the Western world [1, 2]. In his research letter entitled 'Deficiency of essential fatty acids and atherosclerosis, etcetera' published in the Lancet in 1956 , Sinclair provided evidence that cardiovascular disease and, in particular, atherosclerosis, might be associated with a deficiency of what we now call long-chain polyunsaturated fatty acids; he suggested that the etcetera pointed to the likelihood that diseases other than cardiovascular disease might be related to a deficiency in fatty acids [2, 3]. One of his students at Oxford, David Horrobin, was instrumental in establishing a theoretical framework demonstrating that this might be true of neuropsychiatric disorders . In turn, it was my very great privilege and honour to collaborate with, and be taught by, the late David Horrobin while establishing that fatty acid interventions might indeed have a therapeutic part to play in neuropsychiatric disorders ranging from depression to Huntington's disease (chorea) [5, 6].
In December 2007 the Organizing and Scientific Committee of the 3rd International Congress on Brain & Behaviour invited me to chair a session on the theme of fatty acids and neuropsychiatric disorders. This supplement is based on the proceedings of that meeting and includes papers co-authored by Dr. Marcelo Bustos, Professor Graeme Bydder, Professor Massimo Cocchi, Dr. Serena Counsell, Dr. Gavin Hamilton, Professor Brian Ross, Dr. Nadeem Saeed, Dr. Lucio Tonello, Dr. Ian Treasaden, Dr. Sofia Tsaluchidu and me. In the first paper , evidence is provided from the in vivo 31-phosphorus neurospectroscopy phosphodiester peak which indexes the phosphorylated polar head groups glycerophosphorylcholine and glycerophosphorylethanolamine that exhaled ethane is a biomarker of cerebral n-3 polyunsaturated fatty acid peroxidation in humans, a finding which clearly may have implications for the use of this non-invasive biomarker in future research. The second paper , entitled 'The use of artificial neural networks to study fatty acids in neuropsychiatric disorders' demonstrates for the first time that the self-organizing map, an unsupervised competitive-learning network algorithm which forms a nonlinear projection of a high-dimensional data manifold on a regular, low-dimensional grid, is an optimal type of artificial neural network to use for the task of analyzing platelet fatty acids in neuropsychiatric disorders. Cigarette smoking appears to be relatively common in sufferers of certain neuropsychiatric disorders, such as schizophrenia. It is important, therefore, to ascertain the extent to which smoking is a confounder when studying oxidative stress in such disorders. This is the subject of the third paper , 'A comparison of oxidative stress in smokers and non-smokers: an in vivo human quantitative study of n-3 lipid peroxidation', which has a surprising result. The fourth paper , 'Fatty acids and oxidative stress in psychiatric disorders', is a systematic review of published evidence for increased oxidative stress in such disorders. The fifth paper  presents the first voxel-based morphometry study of grey matter changes in the whole brain in schizophrenia associated with a history of seriously and violently offending. Finally, the last paper  describes cerebral spectroscopic and oxidative stress studies in patients with schizophrenia who have dangerously violently offended.
I should like to express my thanks to the organizers of the conference and to the editor and staff of BMC Psychiatry, with particular thanks to Ros Dignon of BioMed Central, who has been of immense help in putting this supplement together.
This article has been published as part of BMC Psychiatry Volume 8 Supplement 1, 2008: Fatty acids and neuropsychiatric disorders. The full contents of the supplement are available online at http://www.biomedcentral.com/1471-244X/8?issue=S1.
- Burr ML: Lessons from the story of n-3 fatty acids. Am J Clin Nutr. 2000, 71 (1 Suppl): 397S-398S.PubMedGoogle Scholar
- Puri BK: Cardiovascular disease and depression: the PUFA connection. Int J Clin Pract. 2008, 62: 355-357. 10.1111/j.1742-1241.2007.01649.x.PubMedView ArticleGoogle Scholar
- Sinclair HM: Deficiency of essential fatty acids and atherosclerosis, etcetera. Lancet. 1956, 270: 381-383.PubMedGoogle Scholar
- Peet M, Glen I, Horrobin DF, (Eds): Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2003, Carnforth: Marius Press, 2Google Scholar
- Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF: Eicosapentaenoic acid treatment in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract. 2001, 55: 560-563.PubMedGoogle Scholar
- Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H: Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005, 65: 286-292. 10.1212/01.wnl.0000169025.09670.6d.PubMedView ArticleGoogle Scholar
- Puri BK, Counsell SJ, Ross BM, Hamilton G, Bustos MG, Treasaden IH: Evidence from in vivo 31-phosphorus magnetic resonance spectroscopy phosphodiesters that exhaled ethane is a biomarker of cerebral n-3 polyunsaturated fatty acid peroxidation in humans. BMC Psychiatry. 2008, 8 (Suppl 1): S2-10.1186/1471-244X-8-S1-S2.PubMedPubMed CentralView ArticleGoogle Scholar
- Cocchi M, Tonello L, Tsaluchidu S, Puri BK: The use of artificial neural networks to study fatty acids in neuropsychiatric disorders. BMC Psychiatry. 2008, 8 (Suppl 1): S3-10.1186/1471-244X-8-S1-S3.PubMedPubMed CentralView ArticleGoogle Scholar
- Puri BK, Treasaden IH, Cocchi M, Tsaluchidu S, Tonello L, Ross BM: A comparison of oxidative stress in smokers and non-smokers: an in vivo human quantitative study of n-3 lipid peroxidation. BMC Psychiatry. 2008, 8 (Suppl 1): S4-10.1186/1471-244X-8-S1-S4.PubMedPubMed CentralView ArticleGoogle Scholar
- Tsaluchidu S, Cocchi M, Tonello L, Puri BK: Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008, 8 (Suppl 1): S5-10.1186/1471-244X-8-S1-S5.PubMedPubMed CentralView ArticleGoogle Scholar
- Puri BK, Counsell SJ, Saeed N, Bustos MG, Treasaden IH, Bydder GM: Regional grey matter volumetric changes in forensic schizophrenia patients: an MRI study comparing the brain structure of patients who have seriously and violently offended with that of patients who have not. BMC Psychiatry. 2008, 8 (Suppl 1): S6-10.1186/1471-244X-8-S1-S6.PubMedPubMed CentralView ArticleGoogle Scholar
- Treasaden IH, Puri BK: Cerebral spectroscopic and oxidative stress studies in patients with schizophrenia who have dangerously violently offended. BMC Psychiatry. 2008, 8 (Suppl 1): S7-10.1186/1471-244X-8-S1-S7.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.